Sujata Tyagi Dayal net worth and biography

Sujata Dayal Biography and Net Worth

Director of Emergent Biosolutions

Ms. Dayal was appointed to the Emergent board in July, 2022. Since March 2020, she has served as vice president and global chief compliance officer of Medline Industries, Inc. Over the last two decades, Ms. Dayal has held roles of growing responsibility in compliance with a focus on healthcare compliance in the pharmaceutical and medical device industry. She previously served as a vice president, healthcare compliance at Johnson & Johnson from 2013 to 2020. Prior to that, she served on senior executive roles in ethics and compliance at Biomet, Inc. and Abbott Laboratories.

Ms. Dayal is an attorney by training with expertise in transactional work, regulatory law, privacy and compliance, including healthcare compliance and anti-corruption. She earned her J.D. from Chicago-Kent College of Law, LL.M. from Columbia University School of Law, LL.B. from Rajasthan University Law School in Jaipur, India, and B.A. Honors degree in Political Science from Lady Shri Ram College in New Delhi, India.

What is Sujata Tyagi Dayal's net worth?: The estimated net worth of Sujata Tyagi Dayal is at least $929.20 thousand as of May 1st, 2026. Dayal owns 100,563 shares of Emergent Biosolutions stock worth more than $929,202 as of May 6th. This net worth approximation does not reflect any other assets that Dayal may own. Learn More about Sujata Tyagi Dayal's net worth.
How do I contact Sujata Tyagi Dayal?: The corporate mailing address for Dayal and other Emergent Biosolutions executives is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. Emergent Biosolutions can also be reached via phone at (240) 631-3200 and via email at [email protected]. Learn More on Sujata Tyagi Dayal's contact information.
Has Sujata Tyagi Dayal been buying or selling shares of Emergent Biosolutions?: Over the course of the past ninety days, Sujata Tyagi Dayal has sold $115,592.40 in Emergent Biosolutions stock. Most recently, Sujata Tyagi Dayal sold 13,761 shares of the business's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $8.40, for a transaction totalling $115,592.40. Following the completion of the sale, the director now directly owns 100,563 shares of the company's stock, valued at $844,729.20. Learn More on Sujata Tyagi Dayal's trading history.
Who are Emergent Biosolutions' active insiders?: Emergent Biosolutions' insider roster includes Sujata Dayal (Director), Donald Degolyer (Director), Neal Fowler (Director), Coleen Glessner (EVP), Keith Katkin (Director), Richard Lindahl (CFO), Ronald Richard (Director), and Kathryn Zoon (Director). Learn More on Emergent Biosolutions' active insiders.
Are insiders buying or selling shares of Emergent Biosolutions?: During the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 137,291 shares worth more than $1,267,661.38. The most recent insider tranaction occured on May, 1st when Director Sujata Tyagi Dayal sold 13,761 shares worth more than $115,592.40. Insiders at Emergent Biosolutions own 6.0% of the company. Learn More about insider trades at Emergent Biosolutions.
Information on this page was last updated on 5/1/2026.

Sujata Tyagi Dayal Insider Trading History at Emergent Biosolutions

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/1/2026	Sell	13,761	$8.40	$115,592.40	100,563

Sujata Tyagi Dayal Buying and Selling Activity at Emergent Biosolutions

Emergent Biosolutions Company Overview

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $9.24

$9.10

$9.37

50 Day Range

MA: $8.50

$7.84

$11.12

2 Week Range

Now: $9.24

$4.72

$14.06

Volume

242,065 shs

Average Volume

876,353 shs

Market Capitalization

$477.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.33